MDWD News and Press, MediWound Ltd. From 06/29/21

YAVNE, Israel, June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it received a Complete Response Letter (CRL) from the U...

Siriporn Lin/iStock via Getty Images MediWound (MDWD) rose sharply in the pre-market after its partner Kaken Pharmaceutical (SKKAF) announced that it submitted a new drug application for approval of topical burn therapy KMW-1 in Japan. The new drug application to the Ministry of Hea...

Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s dis...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The earnings calendar is light next week as the first half of the year comes to a close, but Micron (NASDAQ:MU), General...

MediWound (MDWD) completes patient enrollment for the interim assessment of its U.S. EscharEx Phase 2 study for the treatment of venous leg ulcers ((VLUs)).The company said that the interim assessment, meant for futility analysis and potential sample size adjustment, is expected by ...

YAVNE, Israel, June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the enrollment target of patients for an interim assessme...

Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 YAVNE, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrat...

The following slide deck was published by MediWound Ltd. in conjunction with this event. For further details see: Mediwound (MDWD) Investor Presentation - Slideshow

MediWound (MDWD): Q1 GAAP EPS of -$0.10 beats by $0.02.Revenue of $5.85M (+31.8% Y/Y) beats by $0.32M.Press Release For further details see: MediWound EPS beats by $0.02, beats on revenue

MediWound is preparing for NexoBrid's PDUFA date that is scheduled in June of this year. If approved, NexoBrid will be entering a $200M TAM with numerous benefits over the standard-of-care. I provide some background on NexoBrid and point out some key data points that support approval....